AAAAAA
Results:
1-17
|
Results: 17
Authors:
Gravis, G
Mousseau, M
Douillard, JY
Dorval, T
Fabbro, M
Escudier, B
Mignot, L
Viens, P
Citation: G. Gravis et al., Can interleukin-2 reverse anthracyclin chemoresistance in metastatic soft tissue sarcoma patients. Results of a prospective phase II clinical trial, EUR CYTOKIN, 12(2), 2001, pp. 239-243
Authors:
Merad, M
Angevin, E
Wolfers, T
Flament, C
Lorenzi, I
Triebel, F
Escudier, B
Zitvogel, L
Citation: M. Merad et al., Generation of monocyte-derived dendritic cells from patients with renal cell cancer: Modulation of their functional properties after therapy with biological response modifiers (IFN-alpha plus IL-2 and IL-12), J IMMUNOTH, 23(3), 2000, pp. 369-378
Authors:
Negrier, S
Maral, J
Drevon, M
Vinke, J
Escudier, B
Philip, T
Citation: S. Negrier et al., Long-term follow-up of patients with metastatic renal cell carcinoma treated with intravenous recombinant interleukin-2 in Europe, CA J SCI AM, 6, 2000, pp. S93-S98
Authors:
Delord, JP
Raymond, E
Chaouche, M
Ruffie, P
Ducreux, M
Faivre, S
Boige, V
Le Chevalier, T
Rixe, O
Baudin, E
Pautier, P
Rodier, JM
Chouaki, N
Escudier, B
Kayitalire, L
Armand, JP
Citation: Jp. Delord et al., A dose-finding study of gemcitabine and vinorelbine in advanced previouslytreated malignancies, ANN ONCOL, 11(1), 2000, pp. 73-79
Authors:
Escudier, B
Andre, F
Baldeyrou, P
Le Cesne, A
Le Chevalier, T
Tursz, T
Citation: B. Escudier et al., Gene therapy and lung cancer: today and tomorrow., REV MAL RES, 17(1), 2000, pp. 363-370
Authors:
Negrier, S
Caty, A
Lesimple, T
Douillard, JY
Escudier, B
Rossi, JF
Viens, P
Gomez, F
Citation: S. Negrier et al., Treatment of patients with metastatic renal carcinoma with a combination of subcutaneous interleukin-2 and interferon alfa with or without fluorouracil, J CL ONCOL, 18(24), 2000, pp. 4009-4015
Authors:
Haicheur, N
Escudier, B
Dorval, T
Negrier, S
De Mulder, PHM
Dupuy, JM
Novick, D
Guillot, T
Wolf, S
Pouillart, P
Fridman, WH
Tartour, E
Citation: N. Haicheur et al., Cytokines and soluble cytokine receptor induction after IL-12 administration in cancer patients, CLIN EXP IM, 119(1), 2000, pp. 28-37
Authors:
Negrier, S
Ollivier, L
Di Stefano-Louineau, D
Escudier, B
Savary, J
Lasset, C
Thiesse, P
Citation: S. Negrier et al., Response rate accuracy in oncology - Analysis of causes for variation, B CANCER, 87(12), 2000, pp. 927-934
Authors:
Guerra, N
Guillard, M
Angevin, E
Echchakir, H
Escudier, B
Moretta, A
Chouaib, S
Caignard, A
Citation: N. Guerra et al., Killer inhibitory receptor (CD158b) modulates the lytic activity of tumor-specific T lymphocytes infiltrating renal cell carcinomas, BLOOD, 95(9), 2000, pp. 2883-2889
Authors:
Le Cesne, A
Vassal, G
Farace, F
Spielmann, M
Le Chevalier, T
Angevin, E
Valteau-Couanet, D
Fizazi, K
Cojean, I
Llombard, A
Tursz, T
Escudier, B
Citation: A. Le Cesne et al., Combination interleukin-2 and doxorubicin in advanced adult solid tumors: Circumvention of doxorubicin resistance in soft-tissue sarcoma?, J IMMUNOTH, 22(3), 1999, pp. 268-277
Authors:
Escudier, B
Chevreau, C
Lasset, C
Douillard, JY
Ravaud, A
Fabbro, M
Caty, A
Rossi, JF
Viens, P
Bergerat, JP
Savary, J
Negrier, S
Citation: B. Escudier et al., Cytokines in metastatic renal cell carcinoma: Is it useful to switch to interleukin-2 or interferon after failure of a first treatment?, J CL ONCOL, 17(7), 1999, pp. 2039-2043
Authors:
Angevin, E
Glukhova, L
Pavon, C
Chassevent, A
Terrier-Lacombe, MJ
Goguel, AF
Bougaran, J
Ardouin, P
Court, BH
Perrin, JL
Vallancien, G
Triebel, F
Escudier, B
Citation: E. Angevin et al., Human renal cell carcinoma xenografts in SCID mice: Tumorigenicity correlates with a poor clinical prognosis, LAB INV, 79(7), 1999, pp. 879-888
Authors:
Dorval, T
Negrier, S
Chevreau, C
Avril, MF
Baume, D
Cupissol, D
Oskam, R
de Peuter, R
Vinke, J
Herrera, L
Escudier, B
Citation: T. Dorval et al., Randomized trial of treatment with cisplatin and interleukin-2 either alone or in combination with interferon-alpha-2a in patients with metastatic melanoma, CANCER, 85(5), 1999, pp. 1060-1066
Authors:
Elkahwaji, J
Robin, MA
Berson, A
Tinel, M
Letteron, P
Labbe, G
Beaune, P
Elias, D
Rougier, P
Escudier, B
Duvillard, P
Pessayre, D
Citation: J. Elkahwaji et al., Decrease in hepatic cytochrome P450 after interleukin-2 Immunotherapy, BIOCH PHARM, 57(8), 1999, pp. 951-954
Authors:
Culine, S
Bekradda, M
Kramar, A
Rey, A
Escudier, B
Droz, JP
Citation: S. Culine et al., Prognostic factors for survival in patients with brain metastases from renal cell carcinoma, CANCER, 83(12), 1998, pp. 2548-2553
Authors:
Escudier, B
Le Cesne, A
Angevin, E
Citation: B. Escudier et al., Immunotherapeutic approaches in metastatic renal cell carcinoma and melanoma, RESEARCH IN, 1998, pp. 189-204
Authors:
Zitvogel, L
Fernandez, N
Lozier, A
Wolfers, J
Merad, M
Angevin, E
Amigorena, S
Escudier, B
Citation: L. Zitvogel et al., Immunotherapy for cancer by dendritic cell therapy - From preclinical bases to therapeutic trial designs, EUROCANCER 98, 1998, pp. 289-291
Risultati:
1-17
|